ICCC PE Ratio & Valuation, Is ICCC Overvalued

Historical Valuation

ImmuCell Corp (ICCC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -59.10. The fair price of ImmuCell Corp (ICCC) is between +Inf to +Inf according to relative valuation method. Compared to the current price of 6.33 USD , ImmuCell Corp By Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：6.33

Fair

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is ImmuCell Corp (ICCC) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

ImmuCell Corp (ICCC) has a current Price-to-Book (P/B) ratio of 2.12. Compared to its 3-year average P/B ratio of 1.62, the current P/B ratio is approximately 30.97% higher. Relative to its 5-year average P/B ratio of 1.79, the current P/B ratio is about 18.39% higher. ImmuCell Corp (ICCC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -8.53%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.69%, the current FCF yield is about -100.00% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ICCC competitors is 7.08, providing a benchmark for relative valuation. ImmuCell Corp Corp (ICCC.O) exhibits a P/S ratio of --, which is -100% above the industry average. Given its robust revenue growth of -1.61%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ICCC increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ICCC in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ICCC currently overvalued or undervalued?

What is ImmuCell Corp (ICCC) fair value?

ICCC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of ImmuCell Corp (ICCC) is between +Inf to +Inf according to relative valuation method.

How does ICCC's valuation metrics compare to the industry average?

The average P/S ratio for ICCC's competitors is 7.08, providing a benchmark for relative valuation. ImmuCell Corp Corp (ICCC) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of -1.61%, this premium appears unsustainable.

What is the current P/B ratio for ImmuCell Corp (ICCC) as of Apr 01 2026?

As of Apr 01 2026, ImmuCell Corp (ICCC) has a P/B ratio of 2.12. This indicates that the market values ICCC at 2.12 times its book value.

What is the current FCF Yield for ImmuCell Corp (ICCC) as of Apr 01 2026?

As of Apr 01 2026, ImmuCell Corp (ICCC) has a FCF Yield of 0.00%. This means that for every dollar of ImmuCell Corp's market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for ImmuCell Corp (ICCC) as of Apr 01 2026?

As of Apr 01 2026, ImmuCell Corp (ICCC) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of ImmuCell Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for ImmuCell Corp (ICCC) as of Apr 01 2026?

As of Apr 01 2026, ImmuCell Corp (ICCC) has a Forward P/S ratio of 0.00. This means the market is valuing ICCC at $0.00 for every dollar of expected revenue over the next 12 months.

ICCC Valuation